January 13, 2015

Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics

September 12, 2013

Fedora Pharmaceuticals Demonstrates that FPI–1465 Increases Activity of Certain Antibiotics against Drug-Resistant Bacteria

August 27, 2013

Fedora Pharmaceuticals Unveils Details of Antibiotic Resistance Program in 10 Posters at 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)



Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antibiotics targeting life-threatening microbial drug resistance. Fedora's management and scientific team of staff and collaborators bring a wealth of knowledge and expertise in drug discovery and development as demonstrated by the extensive lists of drugs both in development and in clinical use developed by Fedora's team.

Fedora's pipeline includes the first ever β-Lactamase inhibitors with potent activity against highly resistant bacterial strains including the newly emerging metallo-β-lactamase NDM-1. Fedora is currently advancing these new leads through late stage pre-clinical development and hope to begin human clinical trials by the first quarter of 2014.




"Innovative Approaches for Improved Health"